Epizyme Inc. (NASDAQ:EPZM) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $8.04 and last traded at $8.05, with a volume of 351,013 shares trading hands. The stock had previously closed at $8.16.

A number of equities research analysts have issued reports on EPZM shares. Cowen and Company restated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Mizuho restated a “buy” rating and set a $18.00 price objective on shares of Epizyme in a research report on Monday, June 20th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $26.00 target price on shares of Epizyme in a research note on Monday, June 20th. JMP Securities reaffirmed a “buy” rating and set a $28.00 target price on shares of Epizyme in a research note on Thursday, June 23rd. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $39.00 target price on shares of Epizyme in a research note on Tuesday, June 21st. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Epizyme presently has a consensus rating of “Buy” and a consensus target price of $23.11.

The stock’s market cap is $467.13 million. The stock has a 50-day moving average of $9.61 and a 200 day moving average of $10.42.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. Equities analysts expect that Epizyme Inc. will post ($2.19) EPS for the current year.

In related news, insider Robert A. Copeland sold 4,000 shares of Epizyme stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $10.37, for a total value of $41,480.00. Following the sale, the insider now directly owns 35,538 shares in the company, valued at approximately $368,529.06. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of hedge funds and institutional investors have added to or reduced their stakes in EPZM. Schwab Charles Investment Management Inc. raised its position in Epizyme by 3.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 80,104 shares of the biopharmaceutical company’s stock worth $1,284,000 after buying an additional 2,436 shares during the period. California Public Employees Retirement System acquired a new position in Epizyme during the fourth quarter worth $2,723,000. Finally, Jennison Associates LLC raised its position in Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares during the period.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.